Stocks Health care FDMT
NASDAQ · Health care4D Molecular Therapeutics, Inc. (FDMT)
4D Molecular Therapeutics, Inc. brought in $92M of revenue over the twelve months to June 30, 2026, up 278,712.1% from a year earlier. It posted a net loss of $179.2M. In fiscal 2025 capital spending exceeded operating cash flow by $109.6M. At June 30, 2026 it held $70.4M in cash against $19.6M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.
What 4D Molecular Therapeutics, Inc. does
4D Molecular Therapeutics, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker FDMT.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $85.2M | -$140.1M | -$2.42 | -$109.6M |
| 2024 | $37K | -$160.9M | -$2.98 | -$138.4M |
| 2023 | $20.7M | -$100.8M | -$2.58 | -$78.6M |
| 2022 | $3.1M | -$107.5M | -$3.32 | -$98.2M |
| 2021 | $18M | -$71.3M | -$2.57 | -$78.2M |
| 2020 | $13.6M | -$56.7M | -$8.82 | -$51.9M |
Latest SEC filings
What 4D Molecular Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 13, 2026Quarterly report 10-Q · period to June 30, 2026
- August 13, 2026
- July 20, 2026Other event 8-K
- June 29, 2026
- June 22, 2026
- May 15, 2026Passive stake changed SCHEDULE 13G/A
- May 15, 2026Passive stake changed SCHEDULE 13G/A
- May 12, 2026Passive stake (5% or more) SCHEDULE 13G
- May 7, 2026
- May 7, 2026Quarterly report 10-Q · period to March 31, 2026
Questions about FDMT
What does 4D Molecular Therapeutics, Inc. do?
4D Molecular Therapeutics, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker FDMT.
Is 4D Molecular Therapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $179.2M on revenue of $92M.
How much revenue does 4D Molecular Therapeutics, Inc. make?
Over the twelve months to June 30, 2026 4D Molecular Therapeutics, Inc. reported revenue of $92M. That is 278,712.1% more than a year earlier.
When did 4D Molecular Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 22, 2026.
Similar companies
Follow FDMT
Get an email when 4D Molecular Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow FDMT: get an email when it filesWhere the numbers come from
Financial figures are the values 4D Molecular Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.